NCCN Pharmacy Updates: The Role of Tyrosine Kinase Inhibitors in Pediatric Acute Lymphoblastic Leukemia
It is important for health care professionals caring for pediatric patients with ALL to recognize aspects of optimal dosing and frequency, appropriate use in particular genomic alterations, mechanisms of resistance, and patient-specific counseling points to ensure efficacy and compliance of TKIs.
Category
  • Acute Lymphoblastic Leukemia
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Event date August 24, 2022
NCCN Pharmacy Updates: Navigating Advances in Targeted Therapies for Advanced Esophageal, Esophagogastric Junction (EGJ) and Gastric Cancers
The standards of care in the first-line setting for the treatment of advanced or metastatic esophageal, esophagogastric junction and gastric cancer are evolving rapidly. There is a need to review the current landscape of treatment regimens and understand how to incorporate the new standards of care to effectively treat this patient population.
Category
  • Gastric/Esophageal Cancer
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Event date August 8, 2022
NCCN Pharmacy Updates: Updates in the Management of Indolent Non-Hodgkin Lymphomas
Pharmacists play a critical role in patient education, monitoring, and management of treatment-related toxicities and would benefit from a comprehensive review of the novel treatments for indolent non-Hodgkin lymphomas.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Event date October 7, 2022
Monthly Oncology Tumor Boards: Management of Non-Metastatic Prostate Cancer
Clinicians need to be knowledgeable about newer tools that can improve risk stratification, and they need to understand when these tools have the possibility to change management so that unnecessary testing can be avoided. In addition, clinicians should be educated about the heterogeneity among risk groups, so that nuanced discussions with patients can inform decisions surrounding active surveillance.
Category
  • Prostate Cancer
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Event date July 6, 2022
Monthly Oncology Tumor Boards: Updates in the Treatment of Nasopharyngeal Carcinoma
Clinical trials are continuing to investigate the role of induction chemotherapy prior to systemic therapy/radiation therapy for patients with locoregionally advanced nasopharyngeal carcinoma. New evidence regarding the addition of a PD-1 inhibitor to gemcitabine/cisplatin provides an emerging avenue of treatment for patients with recurrent or metastatic disease. It is important for clinicians to remain current on emerging treatment options for patients with nasopharyngeal carcinoma.
Category
  • Head and Neck Cancers
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Event date August 29, 2022
Monthly Oncology Tumor Boards: Treatment of Patients with Kidney Cancer
Adjuvant treatment options for patients with advanced renal cell carcinoma (RCC) following surgery are continually evolving, and new treatment options for different stages of RCC are being approved. It can be challenging for clinicians to remain up-to-date on these updates.
Category
  • Kidney Cancer
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Event date October 25, 2022
Monthly Oncology Tumor Boards: Management of Well-Differentiated Grade 3 Neuroendocrine Tumors
It is important to inform clinicians about this new section of the NCCN Guidelines for Neuroendocrine and Adrenal Tumors, which include recommendations for the evaluation, management, and surveillance of well-differentiated G3 NETs. Keeping clinicians abreast of updated treatment options may help improve clinical decision-making to better address patients’ medical needs.
Category
  • Neuroendocrine Tumors
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Event date June 23, 2022